1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Xerostomia - Pipeline Review, H2 2014

Xerostomia - Pipeline Review, H2 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 41 pages

Xerostomia - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Xerostomia - Pipeline Review, H2 2014’, provides an overview of the Xerostomia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Xerostomia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Xerostomia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Xerostomia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Xerostomia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Xerostomia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Xerostomia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Xerostomia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Xerostomia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Xerostomia - Pipeline Review, H2 2014
Table of Contents
Introduction 5
Global Markets Direct Report Coverage 5
Xerostomia Overview 6
Therapeutics Development 7
Pipeline Products for Xerostomia - Overview 7
Pipeline Products for Xerostomia - Comparative Analysis 8
Xerostomia - Therapeutics under Development by Companies 9
Xerostomia - Therapeutics under Investigation by Universities/Institutes 10
Xerostomia - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Xerostomia - Products under Development by Companies 13
Xerostomia - Products under Investigation by Universities/Institutes 14
Xerostomia - Companies Involved in Therapeutics Development 15
Acacia Pharma Ltd. 15
Hadasit Medical Research Services and Development Ltd 16
Kadmon Corporation, LLC 17
Parion Sciences, Inc. 18
Xerostomia - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
APD-515 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Gene Therapy to Activate Aquaporin-1 for Xerostomia - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Gene Therapy to Activate Aquaporin-1 for Xerostomia - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
HYPER-IL-6 - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
P-552 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Xerostomia - Recent Pipeline Updates 35
Xerostomia - Dormant Projects 36
Xerostomia - Product Development Milestones 37
Featured News and Press Releases 37
Oct 15, 2013: Acacia Pharma Announces Positive Phase II Results With APD515 for Xerostomia in Advanced Cancer 37
Jul 25, 2011: Acacia Pharma Initiates Phase II Clinical Trial With APD515 For Xerostomia 38
Feb 07, 2011: Acacia Pharma Completes Phase I Clinical Trial With APD515 For Xerostomia 38
Jan 06, 2011: Acacia Pharma Starts Clinical Trial With APD515 In Xerostomia 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41

List of Tables

Number of Products under Development for Xerostomia, H2 2014 7
Number of Products under Development for Xerostomia - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Products under Investigation by Universities/Institutes, H2 2014 14
Xerostomia - Pipeline by Acacia Pharma Ltd., H2 2014 15
Xerostomia - Pipeline by Hadasit Medical Research Services and Development Ltd, H2 2014 16
Xerostomia - Pipeline by Kadmon Corporation, LLC, H2 2014 17
Xerostomia - Pipeline by Parion Sciences, Inc., H2 2014 18
Assessment by Monotherapy Products, H2 2014 19
Number of Products by Stage and Target, H2 2014 21
Number of Products by Stage and Mechanism of Action, H2 2014 23
Number of Products by Stage and Route of Administration, H2 2014 25
Number of Products by Stage and Molecule Type, H2 2014 27
Xerostomia Therapeutics - Recent Pipeline Updates, H2 2014 35
Xerostomia - Dormant Projects, H2 2014 36

List of Figures

Number of Products under Development for Xerostomia, H2 2014 7
Number of Products under Development for Xerostomia - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 11
Assessment by Monotherapy Products, H2 2014 19
Number of Products by Top 10 Targets, H2 2014 20
Number of Products by Stage and Top 10 Targets, H2 2014 21
Number of Products by Top 10 Mechanism of Actions, H2 2014 22
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 23
Number of Products by Top 10 Routes of Administration, H2 2014 24
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 25
Number of Products by Top 10 Molecule Types, H2 2014 26
Number of Products by Stage and Top 10 Molecule Types, H2 2014 27

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Opioid Market in the US

  • December 2016
    14 pages
  • Opioid  

  • United States  

View report >

Therapy Market in Denmark - Forecast

  • December 2016
    12 pages
  • Therapy  

  • Denmark  

View report >

Related Market Segments :

Therapy
Clinical Trial
Cancer

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.